Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Newell

Showing results (361-370 of 519) with videos related to

Pageof 52
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitroE Marshman, D R Newell, A H Calvert, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)D L Alison, D R Newell, C Sessa, et al.
The New England Journal of Medicine|January 6, 1983
Elevated serum thymosin alpha 1 levels associated with evidence of immune dysregulation in male homosexuals with a history of infectious diseases or Kaposi's sarcomaE M Hersh, J M Reuben, A Rios, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 8, 2015
Is the "Heart Age" Concept Helpful or Harmful Compared to Absolute Cardiovascular Disease Risk? An Experimental StudyCarissa Bonner, Jesse Jansen, Ben R Newell, et al.
Science (New York, N.Y.)|September 12, 2001
Factors in the decline of coastal ecosystemsD Boesch, E Burreson, W Dennison, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1986
5-Ethyl-2'-deoxyuridine: an explanation for its lack of cytotoxic action in vivoA Jeney, S E Barrie, G A Taylor, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2006
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexedClaire L Graham-Cole, Huw D Thomas, Gordon A Taylor, et al.
British Journal of Cancer|September 1, 1991
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancerJ L Mansi, A de Graeff, D R Newell, et al.
Pageof 52

Showing results (361-370 of 519) with videos related to

Sort By:
Pageof 52
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitroE Marshman, D R Newell, A H Calvert, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)D L Alison, D R Newell, C Sessa, et al.
The New England Journal of Medicine|January 6, 1983
Elevated serum thymosin alpha 1 levels associated with evidence of immune dysregulation in male homosexuals with a history of infectious diseases or Kaposi's sarcomaE M Hersh, J M Reuben, A Rios, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 8, 2015
Is the "Heart Age" Concept Helpful or Harmful Compared to Absolute Cardiovascular Disease Risk? An Experimental StudyCarissa Bonner, Jesse Jansen, Ben R Newell, et al.
Science (New York, N.Y.)|September 12, 2001
Factors in the decline of coastal ecosystemsD Boesch, E Burreson, W Dennison, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1986
5-Ethyl-2'-deoxyuridine: an explanation for its lack of cytotoxic action in vivoA Jeney, S E Barrie, G A Taylor, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2006
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexedClaire L Graham-Cole, Huw D Thomas, Gordon A Taylor, et al.
British Journal of Cancer|September 1, 1991
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancerJ L Mansi, A de Graeff, D R Newell, et al.
Pageof 52